Verition Fund Management LLC acquired a new position in shares of Intrexon Corp (NYSE:XON) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,556 shares of the biotechnology company’s stock, valued at approximately $223,000.
Several other institutional investors have also recently added to or reduced their stakes in the company. California Public Employees Retirement System increased its stake in shares of Intrexon by 11.0% during the 1st quarter. California Public Employees Retirement System now owns 29,870 shares of the biotechnology company’s stock worth $458,000 after purchasing an additional 2,970 shares during the last quarter. Macquarie Group Ltd. increased its stake in shares of Intrexon by 11.8% during the 4th quarter. Macquarie Group Ltd. now owns 40,231 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 4,236 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Intrexon by 9.0% during the 4th quarter. Teachers Advisors LLC now owns 68,326 shares of the biotechnology company’s stock worth $787,000 after purchasing an additional 5,623 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Intrexon by 85.5% during the 4th quarter. SG Americas Securities LLC now owns 13,560 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 6,251 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its stake in shares of Intrexon by 11.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 71,155 shares of the biotechnology company’s stock worth $1,091,000 after purchasing an additional 7,420 shares during the last quarter. Institutional investors own 83.59% of the company’s stock.
Separately, JPMorgan Chase & Co. restated a “neutral” rating and set a $18.00 price objective (down from $22.00) on shares of Intrexon in a research note on Monday, March 5th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $34.67.
Shares of Intrexon opened at $13.94 on Monday, according to Marketbeat. Intrexon Corp has a 52 week low of $10.26 and a 52 week high of $25.30. The stock has a market capitalization of $1.80 billion, a P/E ratio of -15.15 and a beta of 1.05. The company has a current ratio of 2.16, a quick ratio of 1.93 and a debt-to-equity ratio of 0.01.
Intrexon (NYSE:XON) last announced its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.09). Intrexon had a negative net margin of 57.66% and a negative return on equity of 14.96%. The company had revenue of $43.80 million during the quarter, compared to analyst estimates of $60.43 million. During the same quarter last year, the company posted ($0.26) EPS. The firm’s quarterly revenue was down 18.4% on a year-over-year basis. equities analysts expect that Intrexon Corp will post -0.86 earnings per share for the current year.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NYSE:XON).
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.